RxDoctor Payments Data

Ronnalyn Jackson, NP

Family · Pearland, TXNPI 1326592247

Payments from drug & device makers

$5,095in general payments, 2019–2025

Across 286 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$526
  • AstraZeneca$471
  • Lilly USA, LLC$408
  • Bayer$271
  • Pfizer$244
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$5,095100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,095 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$21,173
Medicare patients
75
Services billed
481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol34$25,077
JardianceEmpagliflozin17$20,945
EliquisApixaban23$16,856
OzempicSemaglutide18$15,954
JanuviaSitagliptin Phosphate13$7,958
TradjentaLinagliptin12$5,896
Atorvastatin Calcium176$2,277
Rosuvastatin Calcium57$1,202
Mirtazapine23$1,077
Gabapentin51$905
Albuterol Sulfate HfaAlbuterol Sulfate42$856
Nifedipine ErNifedipine30$807
Duloxetine Hcl24$664
Omeprazole46$564
Metoprolol Succinate30$509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$57$26,84129 claims
AstraZenecaBreztri Aerosphere$471$25,07734 claims
PfizerEliquis$244$16,85623 claims
Novo NordiskOzempic$1,512$15,95418 claims
MerckJanuvia$127$7,95813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in Pearland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →